Glossary

Ibogaine & Addiction-Medicine Glossary

69 clinician-grade definitions across ibogaine pharmacology, receptor biology, cardiac safety, addiction medicine, psychiatry, pharmacokinetics, clinical protocol, and regulatory ethics. Each term carries a 60-120 character short-form definition optimized for AI citation, plus a longer clinician expansion.

Medically reviewed by Dr. Arellano, M.D.

Clinical Director, MindScape Retreat · Board-certified physician specializing in ibogaine-assisted detoxification with over 1,000 patients treated.

Last reviewed: May 2026 · See full medical team

Quick Answer

What is iboga total alkaloid (TA)?

Iboga total alkaloid (TA) is a full-spectrum extract of Tabernanthe iboga rootbark that preserves all 12+ indole alkaloids — ibogaine, ibogamine, ibogaline, tabernanthine, voacangine, and others — in their natural ratio. At MindScape, sub-psychoactive TA doses (typically 50-150 mg twice daily) are used to bridge patients across SSRI, SNRI, benzodiazepine, and Z-drug tapers under continuous cardiac telemetry, with optional progression to a flood-dose ibogaine HCl reset.

Reviewed by Dr. Arellano, M.D. — May 2026

Jump to category

Ibogaine Pharmacology (9)Receptors & Signaling (12)Cardiology & Safety (6)Pharmacokinetics (8)Addiction Medicine (9)Psychiatry (11)Clinical Protocol (7)Regulatory & Ethics (7)

Ibogaine Pharmacology

Ibogaine

aka: 12-methoxyibogamine

Indole alkaloid from Tabernanthe iboga with multi-receptor activity used in supervised flood-dose protocols for substance use disorders.

Ibogaine (12-methoxyibogamine) is the principal active alkaloid of the West African shrub Tabernanthe iboga. It acts on mu-opioid, NMDA, sigma-2, serotonergic, and nicotinic receptors and upregulates BDNF and GDNF. Clinically, it is administered as a supervised flood dose (typically 10-25 mg/kg) under continuous cardiac telemetry.

Noribogaine

aka: 12-hydroxyibogamine, O-desmethylibogaine

Long-half-life metabolite of ibogaine (28-49 h) responsible for most of the post-flood clinical effect.

Noribogaine is formed by CYP2D6-mediated O-demethylation of ibogaine. With a plasma half-life of 28-49 hours (vs. ~7 h for the parent), it dominates total drug exposure after ~12 h post-dose and is implicated in the long-tail anti-craving and mood-stabilizing effects. It is also a kappa-opioid agonist and a serotonin reuptake inhibitor.

See also: Ibogaine, CYP2D6, QT Prolongation

Total Alkaloid (TA)

aka: iboga TA, full-spectrum iboga

Full-spectrum extract containing all 12+ indole alkaloids of Tabernanthe iboga, used at sub-psychoactive doses for taper bridging.

TA is a standardized extract that preserves the full alkaloid spectrum of the iboga rootbark — ibogaine, ibogamine, ibogaline, tabernanthine, voacangine, and others — in their natural ratio. At MindScape, sub-psychoactive doses (typically 50-150 mg BID) are used to bridge patients across SSRI/SNRI/benzodiazepine tapers prior to a flood-dose ibogaine HCl reset.

See also: Ibogaine, Ibogamine, Voacangine, Ibogaline

Ibogamine

Minor iboga alkaloid lacking the 12-methoxy group; weaker NMDA antagonist with minimal QT effect.

Ibogamine is structurally ibogaine without the C12 methoxy substituent. It retains some NMDA-antagonist activity but has a substantially reduced effect on hERG/IKr channels, contributing to TA's favorable cardiac profile relative to pure ibogaine HCl at equivalent total alkaloid mass.

Ibogaline

Minor 12-methoxy-, 13-hydroxy iboga alkaloid found in TA.

Ibogaline differs from ibogaine by an additional hydroxyl at C13. Pharmacology in humans is sparsely characterized but it appears in TA at low single-digit percent and contributes to the multi-receptor profile of full-spectrum extracts.

Tabernanthine

Iboga alkaloid with serotonergic activity, present in TA at single-digit percent.

Tabernanthine is a structural analogue of ibogaine with documented activity at 5-HT receptors. Like ibogamine and voacangine, it is part of the natural alkaloid mixture in iboga rootbark and is preserved in TA.

Voacangine

Iboga precursor alkaloid; biosynthetic source of ibogaine.

Voacangine is found in Voacanga africana and is the biosynthetic precursor that is decarbomethoxylated to yield ibogaine. It is the most common semi-synthetic source for pharmaceutical-grade ibogaine HCl.

Tabernanthe iboga

West African shrub whose rootbark is the natural source of ibogaine and TA.

Tabernanthe iboga (family Apocynaceae) is native to Gabon, Cameroon, and the Republic of Congo. Its rootbark has been used ceremonially in Bwiti tradition for centuries and is the natural source of all 12+ iboga indole alkaloids.

See also: Ibogaine, Total Alkaloid (TA), Bwiti

Psychoplastogen

Compound that produces rapid, sustained changes in synaptic structure via TrkB/BDNF signaling.

Coined by Olson (2018), the term describes compounds — including psilocybin, ketamine, DMT, and ibogaine — that drive rapid neuroplasticity. Mechanistically, they share a final-common-pathway involving TrkB receptor activation and downstream BDNF expression, distinguishing them from classical antidepressants.

Mu-Opioid Receptor (MOR)

aka: MOR, OPRM1

G-protein-coupled receptor that mediates opioid analgesia, euphoria, dependence, and respiratory depression.

MOR is the primary target of clinical opioids (morphine, fentanyl, methadone). Ibogaine is a low-affinity partial modulator with biased signaling that appears to attenuate withdrawal without producing classical opioid effects; noribogaine adds kappa-opioid agonism to the picture.

Kappa-Opioid Receptor (KOR)

aka: KOR, OPRK1

Opioid receptor subtype implicated in dysphoria, stress, and craving regulation.

KOR activation is generally dysphoric and aversive. Noribogaine is a moderate KOR agonist; this is hypothesized to contribute to the long-tail mood and craving effects of ibogaine treatment, though the role remains debated.

NMDA Receptor

aka: N-methyl-D-aspartate receptor

Ionotropic glutamate receptor central to learning, memory, and opioid tolerance.

NMDA-receptor antagonism (as with ketamine, memantine, and ibogaine) attenuates opioid tolerance and dependence and is implicated in rapid antidepressant effects. Ibogaine binds the MK-801 site as a non-competitive antagonist.

MK-801 Binding Site

Channel-pore site of NMDA receptor where non-competitive antagonists like ibogaine and ketamine bind.

Named for the prototype antagonist dizocilpine (MK-801), this site lies within the NMDA channel pore and is occupied only when the channel is open — giving use-dependent antagonism that is thought to underpin the favorable side-effect profile of low-trapping antagonists.

Sigma-2 Receptor

aka: σ2, TMEM97

Receptor (TMEM97) implicated in cellular stress response and neuroprotection.

Ibogaine is a moderate sigma-2 ligand. The sigma-2 receptor was molecularly identified as TMEM97 and is involved in cholesterol homeostasis, ER stress, and neuroprotective signaling.

Serotonin Receptors (5-HT)

Family of 14 GPCR/ligand-gated receptor subtypes mediating mood, sleep, appetite, and gut function.

Ibogaine and noribogaine bind multiple 5-HT subtypes (notably 5-HT2A and 5-HT3) and noribogaine is a weak SERT inhibitor. SSRIs and SNRIs target reuptake at SERT to indirectly increase synaptic 5-HT.

Serotonin Transporter (SERT)

Reuptake transporter for serotonin; primary target of SSRIs and SNRIs.

SERT removes 5-HT from the synapse for recycling. SSRIs (fluoxetine, sertraline, escitalopram, paroxetine) and SNRIs (venlafaxine, duloxetine) inhibit SERT to indirectly raise synaptic 5-HT.

BDNF

aka: Brain-Derived Neurotrophic Factor

Neurotrophin that drives synaptic plasticity, axon growth, and neuronal survival via TrkB signaling.

BDNF is the most-studied neurotrophin in depression and addiction research. Ibogaine, ketamine, and psilocybin all upregulate BDNF, which is thought to underpin their rapid antidepressant and anti-craving effects.

See also: GDNF, TrkB Receptor, Psychoplastogen

GDNF

aka: Glial Cell Line-Derived Neurotrophic Factor

Neurotrophin selective for dopaminergic neurons; sustainedly upregulated by ibogaine.

GDNF promotes the survival and function of dopaminergic neurons in the VTA and substantia nigra. He et al. (2005) demonstrated that ibogaine produces a sustained GDNF surge that persists beyond the parent drug's elimination — a candidate mechanism for the long-tail anti-craving effect.

TrkB Receptor

aka: NTRK2

Tyrosine kinase receptor for BDNF; entry point for neuroplasticity signaling.

TrkB is the high-affinity receptor for BDNF. Activation drives MAPK, PI3K-Akt, and PLCγ pathways that ultimately produce synaptic protein synthesis and dendritic remodeling.

Ventral Tegmental Area (VTA)

Midbrain dopamine nucleus central to reward, motivation, and addiction.

The VTA projects dopaminergic axons to the nucleus accumbens, prefrontal cortex, and amygdala, forming the mesolimbic and mesocortical reward pathways. GDNF upregulation in the VTA is implicated in ibogaine's anti-craving effect.

Dopamine

Catecholamine neurotransmitter mediating reward prediction, motivation, and motor control.

Dopamine signaling through D1-D5 receptors regulates the brain's reward system. Chronic substance use produces hypodopaminergic states that contribute to anhedonia and craving — a deficit ibogaine is hypothesized to repair via GDNF-mediated dopaminergic neuron support.

Cardiology & Safety

QT Prolongation

aka: QTc prolongation, long QT

Prolongation of the cardiac repolarization interval associated with risk of torsades de pointes.

QT prolongation reflects delayed ventricular repolarization, often via hERG/IKr blockade. Ibogaine and noribogaine both prolong QTc. Continuous telemetry, electrolyte optimization (K+ ≥ 4.0, Mg2+ ≥ 2.0), and pre-treatment ECG screening are mandatory.

hERG / IKr

aka: Kv11.1, KCNH2

Cardiac potassium channel; blockade prolongs QT and increases torsades risk.

The hERG channel mediates the rapid delayed-rectifier potassium current (IKr) responsible for cardiac repolarization. Ibogaine and noribogaine block hERG dose-dependently. TA, with its multi-alkaloid composition, has a more favorable hERG profile per unit clinical effect.

Torsades de Pointes

aka: TdP

Polymorphic ventricular tachycardia precipitated by long QT; can degenerate to ventricular fibrillation.

TdP is the principal cardiac risk of ibogaine treatment. It typically presents as a self-terminating run of polymorphic VT but can degenerate to VF. Risk is mitigated by patient screening, electrolyte optimization, telemetry, and ACLS-equipped facility.

Cardiac Telemetry

Continuous ECG monitoring with real-time QT/rhythm surveillance.

Onsite telemetry runs from pre-dose through 72-96 hours post-flood (the noribogaine elimination tail). Alarms are configured for QTc thresholds, polymorphic ectopy, and bradycardia.

See also: QT Prolongation, Noribogaine, ACLS

ACLS

aka: Advanced Cardiovascular Life Support

Emergency protocol for cardiac arrest and peri-arrest arrhythmia management.

An ACLS-equipped facility maintains crash cart, defibrillator, IV magnesium and epinephrine, and ACLS-certified staff. Mandatory minimum standard for any ibogaine flood-dose program.

ECG / EKG

Electrocardiogram — surface recording of cardiac electrical activity.

Pre-treatment 12-lead ECG screens for baseline QTc, conduction abnormalities, and structural disease that contraindicate ibogaine. Repeat ECGs are obtained throughout the dose period.

Pharmacokinetics

CYP2D6

Hepatic enzyme that O-demethylates ibogaine to noribogaine; subject to genetic polymorphism.

CYP2D6 metabolizer phenotype (poor / intermediate / extensive / ultrarapid) substantially affects ibogaine and noribogaine exposure. Pharmacogenomic testing is performed pre-treatment because PMs accumulate parent ibogaine longer (extending QT risk) while UMs may rapidly clear it.

CYP3A4

Hepatic enzyme metabolizing ~50% of clinical drugs; minor pathway for ibogaine.

CYP3A4 contributes a minor metabolic pathway for ibogaine. Co-administered strong CYP3A4 inhibitors (ketoconazole, ritonavir, grapefruit) or inducers (rifampin, carbamazepine) are screened during pre-admission med review.

Half-Life

aka: t½

Time required for plasma drug concentration to fall by 50%.

Ibogaine plasma t½ is ~7 hours; noribogaine is 28-49 hours. The disparity is why the noribogaine elimination tail dominates the post-flood pharmacology and why telemetry must extend through ~96 hours.

AUC (Area Under Curve)

Total drug exposure over time; product of concentration × duration.

AUC integrates plasma concentration over time and is the canonical exposure metric. For ibogaine, total AUC is dominated by noribogaine after ~12 hours.

Cmax

Maximum plasma concentration after a dose.

Cmax is the peak observed plasma level. For oral ibogaine HCl, Cmax typically occurs ~2-4 hours post-dose. Cmax of the parent drug correlates with peak QT effect.

Tmax

Time at which maximum plasma concentration is reached.

Tmax characterizes absorption rate. Faster Tmax = faster onset; relevant to dosing strategy and peri-dose monitoring intensity.

Pharmacogenomics

Use of genetic testing to predict drug metabolism and response.

MindScape's baseline workup includes CYP2D6 and CYP3A4 genotyping to anticipate metabolizer status, plus polymorphisms relevant to opioid response (OPRM1) and serotonergic response (SLC6A4).

Drug-Drug Interaction (DDI)

Pharmacokinetic or pharmacodynamic interaction altering the effect of one or both drugs.

Pre-flood medication review screens for QT-prolonging agents (azithromycin, quetiapine, methadone), CYP2D6/3A4 modulators, and serotonergic agents that risk serotonin syndrome with noribogaine's SERT inhibition.

See also: CYP2D6, CYP3A4, Serotonin Syndrome

Addiction Medicine

Opioid Use Disorder (OUD)

DSM-5 diagnosis for problematic opioid use causing clinically significant impairment.

OUD severity is graded mild/moderate/severe by symptom count. FDA-approved medications include methadone, buprenorphine, and naltrexone. Ibogaine remains investigational in the United States but is a recognized treatment in some jurisdictions.

Substance Use Disorder (SUD)

Umbrella DSM-5 diagnosis encompassing problematic use of any substance.

SUD subtypes include alcohol, opioid, stimulant, cannabis, sedative, and tobacco use disorders. Each has distinct withdrawal syndromes and pharmacotherapy options.

Withdrawal Syndrome

Constellation of symptoms following cessation or reduction of a substance after dependence has developed.

Withdrawal syndromes are substance-specific. Opioid withdrawal is acutely uncomfortable but rarely life-threatening; benzodiazepine and alcohol withdrawal can be lethal. Ibogaine attenuates opioid withdrawal in supervised settings.

MAT / MOUD

aka: Medication-Assisted Treatment, Medications for Opioid Use Disorder

FDA-approved opioid pharmacotherapy: methadone, buprenorphine, naltrexone.

Methadone (full agonist), buprenorphine (partial agonist), and naltrexone (antagonist) are evidence-based treatments for OUD. Patients on long-acting MAT (depot buprenorphine, methadone) require structured pre-flood transition planning.

Buprenorphine

aka: Suboxone, Subutex, Sublocade

Partial mu-opioid agonist with high receptor affinity used for OUD treatment.

Buprenorphine has a long half-life and ceiling effect on respiratory depression, making it relatively safe. Its high MOR affinity means it must be cleared before a flood-dose ibogaine, typically 24-72 hours depending on formulation.

Methadone

Long-acting full mu-opioid agonist with intrinsic NMDA-antagonist activity used for OUD.

Methadone has its own QT-prolongation liability and a long, variable half-life (12-150 h). Pre-flood transition typically involves cross-titration to short-acting opioid before final taper.

Naltrexone

aka: Vivitrol, Revia

Mu-opioid antagonist used for OUD and AUD; available oral or as monthly depot injection.

Long-acting depot naltrexone (Vivitrol) requires 28+ days washout before any opioid challenge. Patients on naltrexone are generally not candidates for ibogaine until the depot has fully cleared.

Kindling

Phenomenon where repeated withdrawal episodes worsen with each successive cycle.

First described in alcohol withdrawal, kindling produces progressively more severe symptoms — including seizures — with each cessation. It is a major reason rapid, supervised, single-pass tapers are preferable to repeated home attempts.

Craving

Conscious or sub-conscious urge to use a substance; major driver of relapse.

Craving is mediated by mesolimbic dopamine, glutamate, and stress-system signaling. Long-tail anti-craving effects of ibogaine treatment are hypothesized to reflect GDNF-driven repair of the dopaminergic reward circuit.

Psychiatry

SSRI

aka: Selective Serotonin Reuptake Inhibitor

Antidepressant class that selectively inhibits the serotonin transporter (SERT).

SSRIs include sertraline, escitalopram, fluoxetine, paroxetine, citalopram, and fluvoxamine. They are first-line for major depressive disorder and many anxiety disorders. Discontinuation produces a characteristic syndrome of brain zaps, dizziness, and rebound anxiety.

SNRI

aka: Serotonin-Norepinephrine Reuptake Inhibitor

Antidepressant class that inhibits both serotonin (SERT) and norepinephrine (NET) transporters.

SNRIs include venlafaxine, duloxetine, desvenlafaxine, and milnacipran. They are used for depression, generalized anxiety, and chronic pain. Discontinuation is often more difficult than SSRIs due to the noradrenergic component.

SSRI/SNRI Discontinuation Syndrome

aka: antidepressant discontinuation syndrome, ADS

Withdrawal-like syndrome on stopping or rapidly reducing an SSRI/SNRI.

Symptoms include brain zaps, dizziness, flu-like sensations, irritability, and rebound depression/anxiety. Risk increases with shorter-half-life agents (paroxetine, venlafaxine) and abrupt cessation. Hyperbolic taper is the evidence-based mitigation (Horowitz & Taylor 2019).

Benzodiazepine

aka: benzo

GABA-A positive allosteric modulator class with anxiolytic, sedative, and anticonvulsant effects.

Includes alprazolam, clonazepam, lorazepam, diazepam. Short-half-life benzos (alprazolam) produce more severe withdrawal. Abrupt cessation can be lethal due to seizure risk. Ashton-method cross-titration to diazepam followed by hyperbolic taper is the established protocol.

Z-Drug

aka: non-benzodiazepine hypnotic

GABA-A α1-subunit-selective hypnotic class: zolpidem, zopiclone, eszopiclone, zaleplon.

Z-drugs share GABA-A modulation with benzodiazepines but with α1-subunit selectivity that yields hypnotic effects with reduced anxiolysis and amnesia. Tolerance, dependence, and paradoxical insomnia on cessation are common.

GABA-A Receptor

Pentameric chloride channel; primary inhibitory neurotransmitter receptor in the CNS.

GABA-A is allosterically modulated by benzodiazepines, Z-drugs, alcohol, and barbiturates. Subunit composition (α1-α6, β1-β3, γ1-γ3) determines pharmacology — α1 mediates sedation, α2/α3 mediate anxiolysis.

Serotonin Syndrome

Potentially life-threatening condition from excess serotonergic activity.

Triad of mental-status change, autonomic hyperactivity, and neuromuscular abnormalities. Risk factors include MAOI + SSRI/SNRI/triptan combinations. Noribogaine's mild SERT inhibition is screened against the patient's serotonergic medication list pre-flood.

PTSD

aka: Post-Traumatic Stress Disorder

DSM-5 trauma-related disorder with intrusive, avoidance, mood, and arousal symptoms.

PTSD has high comorbidity with SUDs and treatment-resistant depression. Memory-reconsolidation-window approaches (including psychedelics and dissociatives) are an active research area.

Major Depressive Disorder (MDD)

DSM-5 mood disorder characterized by persistent low mood, anhedonia, and neurovegetative symptoms.

First-line pharmacotherapy is SSRI/SNRI. Non-responders to ≥2 adequate trials meet treatment-resistant depression criteria, where ketamine, esketamine, ECT, and TMS are options.

Treatment-Resistant Depression (TRD)

MDD that has not responded to ≥2 adequate antidepressant trials.

TRD affects ~30% of MDD patients and drives most of the disability burden. Approved interventions include esketamine (Spravato), ECT, and TMS. Psychedelic-assisted therapy is in late-phase trials.

Anhedonia

Inability to feel pleasure from normally rewarding activities; core symptom of depression.

Anhedonia is hypothesized to reflect hypodopaminergic mesolimbic signaling. It is a particularly treatment-resistant symptom and is a target for novel rapid-acting antidepressants.

Clinical Protocol

Flood Dose

aka: psychoactive dose, reset dose

Single supervised psychoactive dose of ibogaine HCl (typically 10-25 mg/kg) for substance-use reset.

The flood dose is the classical clinical-grade ibogaine intervention — a single administration under continuous telemetry that produces 24-36 hours of altered consciousness and 72-96 hours of pharmacologically active tail. It is preceded by structured medical taper and pharmacogenomic workup.

Hyperbolic Taper

Dose-reduction strategy proportional to receptor occupancy curve, producing larger absolute reductions early and smaller reductions late.

Codified by Horowitz & Taylor (2019), hyperbolic taper recognizes that receptor occupancy follows a hyperbolic dose-response curve — meaning the bottom of the dose range produces the steepest occupancy drops. Linear tapers fail because they front-load patients with disproportionate withdrawal at the end.

Ashton Method

Benzodiazepine taper protocol using cross-titration to long-half-life diazepam followed by gradual reduction.

Developed by Prof. C. Heather Ashton (Newcastle, UK), the Ashton Method converts patients from short-acting benzodiazepines to equivalent diazepam doses, then tapers diazepam over months. It is the most-cited benzo-cessation protocol and is integrated with iboga-TA bridging at MindScape.

TA Bridge

Sub-psychoactive iboga total alkaloid dosing (typically 50-150 mg BID) used to span the steepest taper segments.

TA bridging covers the receptor-occupancy gap during hyperbolic SSRI/SNRI/benzo tapers, attenuating discontinuation symptoms without producing a psychedelic experience. To our knowledge, MindScape is currently the only ibogaine facility in North America delivering this protocol.

Integration

Structured therapeutic process of incorporating insights from a psychedelic experience into daily life.

Post-flood integration includes structured therapy sessions, behavioral planning, and aftercare coordination over weeks to months. Integration quality is a major moderator of long-term outcomes.

Aftercare

Ongoing post-discharge support: therapy, peer support, medical follow-up, and relapse prevention.

Evidence-based aftercare combines weekly therapy, MAT continuation if indicated, peer-support attendance, and quarterly medical follow-up. MindScape coordinates aftercare with home-area clinicians.

Regulatory Status

Legal classification of ibogaine: Schedule I in the US, unscheduled in Mexico, regulated medicine in New Zealand and Brazil.

Ibogaine is Schedule I in the United States, meaning no accepted medical use and high abuse potential per DEA classification. It is unscheduled in Mexico (where MindScape operates), a regulated medicine in New Zealand, and approved for use in Brazil under physician supervision.

Schedule I (US)

DEA classification for substances with no accepted medical use and high abuse potential.

Schedule I includes heroin, LSD, cannabis, MDMA, psilocybin, and ibogaine. Research access requires DEA Schedule I registration. Several Schedule I compounds (psilocybin, MDMA) are in late-stage FDA approval pipelines.

IND (Investigational New Drug)

FDA mechanism authorizing clinical investigation of an unapproved drug.

An IND must be filed with the FDA before a Schedule I drug can be administered to patients in the US under research protocols. Several active INDs exist for ibogaine's investigational use.

Right-to-Try / Compassionate Use

Legal pathways allowing access to investigational therapies for patients without other options.

US Right-to-Try (2018) permits access to drugs that have completed Phase I but are not FDA-approved. FDA Expanded Access (compassionate use) is a parallel pathway. Neither currently covers ibogaine in routine practice.

Bwiti

Indigenous Gabonese spiritual tradition centered on ceremonial use of iboga rootbark.

Bwiti is a syncretic religion practiced in Gabon and surrounding regions, integrating older animist traditions with Christian elements. Iboga is used in initiation and healing ceremonies. Modern clinical practice acknowledges Bwiti as the cultural origin of ibogaine pharmacology.

YMYL (Your Money or Your Life)

Google content classification for topics that can affect health, finance, or safety.

YMYL pages — including all medical content — are held to elevated E-E-A-T standards by Google and AI engines. Visible clinician attribution, cited sources, and explicit limitations are mandatory for ranking and AI citation.

E-E-A-T

aka: Experience, Expertise, Authoritativeness, Trustworthiness

Google's quality framework for evaluating content, especially in YMYL domains.

E-E-A-T is not a direct ranking signal but informs both rater guidelines and downstream model behavior. For medical content, it requires named clinician authors with linked credentials, citation of primary literature, and transparent disclosure of limitations.

Methodological Note

Definitions are educational, not personal medical advice.

Glossary entries are written for clinicians, prospective patients, and referring physicians. Where pharmacological data are extrapolated from rodent or in-vitro work, we say so explicitly. For broader context see the 2026 evidence-base review and the onsite taper cohort methodology page.

Clinical Calls

Have a clinical question?

Our medical team takes calls from prospective patients, family members, and referring clinicians.

Schedule a clinical call

100% Confidential · No Obligation